Literature DB >> 35930225

Schizophrenia Outside the Brain.

Aline Gazzola Fragnani Valença1, Bradley Joseph Smith2.   

Abstract

Schizophrenia is a multifactorial mental disorder, characterized by positive symptoms (delusions, hallucinations), negative symptoms (anhedonia, social withdraw), and cognitive symptoms (impairment of memory, learning, and executive functions). Despite the classic symptoms being related to the central nervous system, schizophrenia has been described by recent studies as a systemic disease, affecting other organs, tissues, and systems out of the brain. In this chapter, we summarize the main tissues and systems found affected in schizophrenic patients, both before and after antipsychotic administration. We offer an overview of the recent findings in the field about musculoskeletal system, metabolism, and immune system dysfunctions found in patients as well in models in vitro. We also discuss some of the side effects of certain antipsychotics often related to increased risk of comorbidities in patients with schizophrenia during the treatment.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  Adipose tissue; Immune system; Metabolic syndrome; Schizophrenia; and Psychiatry

Mesh:

Substances:

Year:  2022        PMID: 35930225     DOI: 10.1007/978-3-030-97182-3_4

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   3.650


  72 in total

1.  Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.

Authors:  Stanley N Caroff; Irene Hurford; Janice Lybrand; E Cabrina Campbell
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

Review 2.  Neuroinflammation and Schizophrenia.

Authors:  Peter F Buckley
Journal:  Curr Psychiatry Rep       Date:  2019-07-03       Impact factor: 5.285

3.  Serious mental illness and medical comorbidities: Findings from an integrated health care system.

Authors:  Amber L Bahorik; Derek D Satre; Andrea H Kline-Simon; Constance M Weisner; Cynthia I Campbell
Journal:  J Psychosom Res       Date:  2017-07-08       Impact factor: 3.006

4.  Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.

Authors:  Haya Ascher-Svanum; Allen W Nyhuis; Virginia Stauffer; Bruce J Kinon; Douglas E Faries; Glenn A Phillips; Kory Schuh; A George Awad; Richard Keefe; Dieter Naber
Journal:  Curr Med Res Opin       Date:  2010-10       Impact factor: 2.580

Review 5.  Infectious agents associated with schizophrenia: a meta-analysis.

Authors:  Isabel Arias; Antonio Sorlozano; Enrique Villegas; Juan de Dios Luna; Kathryn McKenney; Jorge Cervilla; Blanca Gutierrez; Jose Gutierrez
Journal:  Schizophr Res       Date:  2011-11-21       Impact factor: 4.939

6.  Anterior Hippocampal-Cortical Functional Connectivity Distinguishes Antipsychotic Naïve First-Episode Psychosis Patients From Controls and May Predict Response to Second-Generation Antipsychotic Treatment.

Authors:  Esther M Blessing; Vishnu P Murty; Botao Zeng; Jijun Wang; Lila Davachi; Donald C Goff
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

7.  Symptoms of schizophrenia. Methods, meanings, and mechanisms.

Authors:  N C Andreasen; S Arndt; R Alliger; D Miller; M Flaum
Journal:  Arch Gen Psychiatry       Date:  1995-05

Review 8.  The Role of Adiponectin in the Pathogenesis of Metabolic Disturbances in Patients With Schizophrenia.

Authors:  Cynthia Yi-An Chen; Kah Kheng Goh; Chun-Hsin Chen; Mong-Liang Lu
Journal:  Front Psychiatry       Date:  2021-01-20       Impact factor: 4.157

9.  Overexpression of Insig-2 inhibits atypical antipsychotic-induced adipogenic differentiation and lipid biosynthesis in adipose-derived stem cells.

Authors:  Chien-Chih Chen; Li-Wen Hsu; Kuang-Tzu Huang; Shigeru Goto; Chao-Long Chen; Toshiaki Nakano
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.